AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02358226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer League/Vocational Training (SL-V)
Description: In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
Study NCT02021630 — intervention group
Intervention type: OTHER
Intervention: Outcomes
Description: No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
Study NCT01134302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Norwood management strategy
Description: Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
Study NCT01134302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Strategy
Description: Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies.
Study NCT04115215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Description: This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.
Study NCT04115215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial current stimulation (tCS)
Description: This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.
Study NCT04115215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
Study NCT03727789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACT Complex-targeting Curaxin CBL0137
Description: Given IA
Study NCT02908750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine tablet dosing
Description: Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
Study NCT02908750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertininb tablet dosing
Description: Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
Study NCT01571011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CURB
Description: The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
Study NCT02499796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hygrovent Gold
Study NCT04392648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets orally.
Study NCT04392648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.
Study NCT02395614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine irrigation
Description: - 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
Study NCT02499796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated and moisture exchanger (HME)
Study NCT02499796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Study NCT02176954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
Study NCT02395614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple antibiotic irrigation
Description: -triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket
Study NCT00851929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
Study NCT00934128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
Study NCT00934128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP
Description: Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
Study NCT00225381 — intervention group
Intervention type: DEVICE
Intervention: A mixing chamber (bymixer)
Description: 2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
Study NCT02176954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
Study NCT01091012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil 20mg oral vs Sildenafil 10mg intravenous
Description: 2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
Study NCT02176954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.
Study NCT03222401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg/kg single infusion of F598
Description: 1 mg/kg single infusion of F598
Study NCT03225001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Description: Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
Study NCT03145675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin (Staged-dose PCI Group)
Description: Enoxaparin 0.5+0.25 mg/kg administered intravenously.
Study NCT03145675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin (Single-dose PCI Group)
Description: Enoxaparin 0.75 mg/kg administered intravenously.
Study NCT03145675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin (High-dose Group)
Description: Enoxaparin 0.75 mg/kg administered intravenously.
Study NCT03145675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin (Standard-dose Group)
Description: Enoxaparin 0.5 mg/kg administered intravenously.
Study NCT02023931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout Extract (BSE)
Description: 1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane.
Study NCT02965417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
Study NCT03222401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg single infusion of F598
Description: 3 mg/kg single infusion of F598
Study NCT02665221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Treatment Arm
Description: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
Study NCT02665221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Preparation H arm
Description: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
Study NCT02252354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-385 Oral Solution
Description: TAK-385 oral radiolabelled solution
Study NCT02252354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 Tablets
Description: TAK-385 tablets 2 X 40 mg
Study NCT02252354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-385 Solution for Intravenous Infusion
Description: TAK-385 intravenous (IV) radiolabelled solution
Study NCT04077554 — intervention group
Intervention type: GENETIC
Intervention: gene expression
Description: determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
Study NCT03710980 — intervention group
Intervention type: DEVICE
Intervention: Oximeter
Description: Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
Study NCT03222401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg single infusion of F598
Description: 10 mg/kg single infusion of F598
Study NCT01279681 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT01279681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given PO
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01279681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01583842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)
Description: 124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later.
Study NCT01583842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-MIBG (carrier added)
Description: 124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later.
Study NCT01583842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) /Computerized tomography (CT)
Description: A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
Study NCT01583842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography (PET) /Computerized tomography (CT)
Description: A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
Study NCT03656991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle intervention
Study NCT00511238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
Study NCT00511238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
Study NCT04503720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLoWI
Description: Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
Study NCT00225381 — intervention group
Intervention type: DEVICE
Intervention: Pneumotachometer cuvette
Description: The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
Study NCT00225381 — intervention group
Intervention type: DEVICE
Intervention: Mass spectrometer sampling port
Description: Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
Study NCT01373749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NO inhalation
Description: NO inhalation was performed as the only treatment for PPHN during the whole course.
Study NCT01373749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NO inhalation continued with sildenafil
Description: NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
Study NCT04503720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
Study NCT01450098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595 Reference Formulation (RF)
Description: Administered orally
Study NCT01450098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Description: Administered orally
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 1 tablet
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 2 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 4 tablets
Study NCT04407741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554+SHR1701
Description: SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 6 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 8 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 9 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 1 tablet
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 2 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 4 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 6 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 8 tablets
Study NCT04164290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 9 tablets
Study NCT03632213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
Study NCT04407741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1701
Description: SHR1701: 30mg/kg, IV, over 30 minutes
Study NCT02363465 — intervention group
Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.
Study NCT03632213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
Study NCT03268941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 Maleate Capsules
Study NCT02656069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-Pen (glucagon injection)
Description: 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Study NCT02656069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lilly Glucagon (glucagon injection [rDNA origin])
Description: 1 mg of Lilly glucagon reconstituted from lyophilized powder
Study NCT03353701 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management (CM)
Description: A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
Study NCT01029743 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
Study NCT01029743 — intervention group
Intervention type: DRUG
Intervention: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
Description: Daily dose, dosage frequency and duration will be decided by physicians
Study NCT00932672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Atkins Diet
Description: Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
Study NCT02819089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
Study NCT03268941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaclopramide
Description: Metaclopramide Tablets
Study NCT03268941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-906 Maleate Placebo
Description: TAK-906 placebo-matching Capsules